Search





Search





US starts engaging drugmakers on putting Trump's MFN pricing into law

ReutersMar 19, 2026 7:56 PM

March 19 (Reuters) - U.S. Health and Human Services chief counselor Chris Klomp said on Thursday the government has begun to read-in pharmaceutical companies on efforts to write into law President Donald Trump's most-favored-nation deals, aimed at aligning U.S. prescription drug costs with those in other wealthy countries.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

What Is Palantir? Can Palantir’s Stock Price Return to $200 in 2026?

TradingKey - In today’s highly competitive technology landscape, Palantir (PLTR), as a company with a core focus on big data and artificial intelligence, has garnered widespread attention through its unique technological advantages and market positioning.

Micron Plunges 10%, Earnings Beat Expectations, Stock Price Falls 30% Consecutively, Can AI Memory Chips Still Be Bought?

TradingKey — Micron Technology’s (MU) recent stock price performance has become a microcosm of shifting sentiment within the AI memory sector. Despite reporting robust earnings, the stock has weakened steadily following the announcement, marking a cumulative decline of nearly 30%. The market is now

IREN, NBIS, and CRWV: The Rise of Neoclouds in the AI Infrastructure Boom

Iris Energy (IREN), Nebius (NBIS) and Coreweave (CRWV) are frequently grouped due to their shared focus on AI infrastructure

Hedge Fund Tycoon Calls ‘Ten-Fold Opportunity,’ Fannie and Freddie Shares Both Surge Over 45%.

TradingKey - During Monday's U.S. Eastern trading session, shares of U.S. mortgage giants Fannie Mae and Freddie Mac experienced a rare surge, boosted by public bullish comments from renowned hedge fund manager Bill Ackman. Fannie Mae (FNMA) shares soared by more than 50%, while Freddie Mac (FMCC) jumped approximately 47%, becoming the focus of the market.

Bitcoin Price Analysis: What Is to Stop BTC from Making Another Run at All-Time Highs in 2026?

This strategic analysis covers institutional BTC price targets from JPMorgan and Fidelity, the impact of the U.S. Strategic Reserve, and whether the four-year cycle is broken. Stay updated on BTC to USD trends and key market risks.

Tradingkey

KeyAI

